Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAN 2020 | Erenumab in migraine with or without aura: cardiovascular safety

Stewart Tepper • 24 May 2020
EAN 2020
Headache Antibodies Erenumab

Stewart Tepper, MD, Professor of Neurology, Geisel School of Medicine at Dartmouth, Hanover, NH, discusses the cardiovascular and cerebrovascular adverse events of erenumab in patients with migraine with or without a history of aura. This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).

More from Stewart Tepper

2:05
AHS highlights: atogepant and zavegepant for migraine treatment
Stewart Tepper • 17 Jun 2022
4:17
Assessing the efficacy of fremanezumab on interictal migraine related burden
Stewart Tepper • 17 Jun 2022
2:00
Discontinuation of anti-CGRP antibodies in non-responders
Stewart Tepper • 17 Jun 2022
5:55
Increased placebo response over time in migraine preventive trials
Stewart Tepper • 17 Jun 2022

Related Videos

3:35
Promising targets in headache research: PACAP
Alan Rapoport • 22 Mar 2024
2:03
What follow-up care is needed for patients with medication overuse headache?
Alan Rapoport • 22 Mar 2024
2:59
Medication overuse headache: current strategies and unmet needs
Morris Levin • 22 Mar 2024
1:26
The potential applications of AI in headache medicine
Morris Levin • 22 Mar 2024
The content of VJNeurology is intended for healthcare professionals